Effect of combined cytostatic cyclosporin A and cytolytic suicide gene therapy on the prevention of experimental graft-versus-host disease
Open Access
- 1 February 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (3) , 201-207
- https://doi.org/10.1038/sj.gt.3301637
Abstract
The immunosuppressive drug cyclosporin A (CsA) represents the standard preventive treatment of graft-versus-host disease (GVHD), the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). However, its efficacy is only partial and many patients develop lethal GVHD despite CsA. A strategy of genetic immunosuppression based on conditional elimination of donor T cells expressing the Herpes simplex type 1 thymidine kinase (TK) suicide gene was recently developed. In this system, ganciclovir (GCV) selectively kills dividing but not quiescent TK T cells. Since CsA is known to have a cytostatic effect on T cells, it could negatively interfere with the division-dependent TK gene therapy. We thus tested whether administration of CsA would antagonize elimination of alloreactive donor TK T cells mediated by GCV in a murine model of GVHD. In vivo experiments revealed that, contrary to GCV, CsA only transiently controlled alloactivation-induced T cell proliferation, and likewise could not prevent lethal GVHD. When T cells resumed proliferation under CsA, they were however still sensitive to GCV. Survival, as well as immune reconstitution, was excellent in mice treated with GCV alone or in combination with CsA. These observations should help to design improved suicide gene therapy trials in the field of allogeneic HSCT.Keywords
This publication has 23 references indexed in Scilit:
- Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graftBlood, 2001
- Preservation of Graft-versus-Infection Effects after Suicide Gene Therapy for Prevention of Graft-versus-Host DiseaseHuman Gene Therapy, 2000
- Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell TransplantationNew England Journal of Medicine, 2000
- Immunological Defects after Suicide Gene Therapy of Experimental Graft-versus-Host DiseaseHuman Gene Therapy, 1999
- The Effect of Graft-versus-Host Disease on T Cell Production and HomeostasisThe Journal of Experimental Medicine, 1999
- Adoptive Immunotherapy for Leukemia: Donor Lymphocytes Transduced with the Herpes Simplex Thymidine Kinase Gene for Remission Induction. Human Gene Therapy Research Institute, Des Moines, Iowa, and Northwestern University School of Medicine, Chicago, IllinoisHuman Gene Therapy, 1998
- HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-LeukemiaScience, 1997
- Successful Allogeneic Transplantation of T-Cell–Depleted Bone Marrow from Closely HLA-Matched Unrelated DonorsNew England Journal of Medicine, 1990
- Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2European Journal of Immunology, 1981
- Use of cyclosporin A in allogeneic bone marrow transplantation in the ratNature, 1979